BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 19788535)

  • 1. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.
    Takata M; Murata H; Saida T
    Pigment Cell Melanoma Res; 2010 Feb; 23(1):64-71. PubMed ID: 19788535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
    Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
    Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
    Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
    Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific dermoscopy patterns and amplifications of the cyclin D1 gene to define histopathologically unrecognizable early lesions of acral melanoma in situ.
    Yamaura M; Takata M; Miyazaki A; Saida T
    Arch Dermatol; 2005 Nov; 141(11):1413-8. PubMed ID: 16301388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations in melanocytic tumors.
    Takata M; Saida T
    J Dermatol Sci; 2006 Jul; 43(1):1-10. PubMed ID: 16750612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-RAF and melanocytic neoplasia.
    Gill M; Celebi JT
    J Am Acad Dermatol; 2005 Jul; 53(1):108-14. PubMed ID: 15965430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT gene mutations and copy number in melanoma subtypes.
    Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
    Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classifying melanocytic tumors based on DNA copy number changes.
    Bastian BC; Olshen AB; LeBoit PE; Pinkel D
    Am J Pathol; 2003 Nov; 163(5):1765-70. PubMed ID: 14578177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin.
    Uribe P; Wistuba II; González S
    Am J Dermatopathol; 2003 Oct; 25(5):365-70. PubMed ID: 14501284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic activation of KIT in distinct subtypes of melanoma.
    Curtin JA; Busam K; Pinkel D; Bastian BC
    J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma.
    Giehl KA; Nägele U; Volkenandt M; Berking C
    J Cutan Pathol; 2007 Jan; 34(1):7-14. PubMed ID: 17214848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF as a melanoma susceptibility candidate gene?
    Laud K; Kannengiesser C; Avril MF; Chompret A; Stoppa-Lyonnet D; Desjardins L; Eychene A; Demenais F; Lenoir GM; Bressac-de Paillerets B;
    Cancer Res; 2003 Jun; 63(12):3061-5. PubMed ID: 12810628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
    Cohen Y; Rosenbaum E; Begum S; Goldenberg D; Esche C; Lavie O; Sidransky D; Westra WH
    Clin Cancer Res; 2004 May; 10(10):3444-7. PubMed ID: 15161700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
    Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
    Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.
    Handolias D; Salemi R; Murray W; Tan A; Liu W; Viros A; Dobrovic A; Kelly J; McArthur GA
    Pigment Cell Melanoma Res; 2010 Apr; 23(2):210-5. PubMed ID: 20088873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanocytic nevi and melanoma: unraveling a complex relationship.
    Damsky WE; Bosenberg M
    Oncogene; 2017 Oct; 36(42):5771-5792. PubMed ID: 28604751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients.
    Kanitakis J; Baldassini S; Lora V; Euvrard S
    Eur J Dermatol; 2010; 20(2):167-71. PubMed ID: 19919912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.